Home
Company
For EU projects

Your partner for EU projects

genOway as validated SME partner for your European research project

The European Commission finances European research and innovation projects, currently under the Horizon 2020 program, with the goal to ensure that international cooperation produces world-class science, removes barriers to innovation and makes it easier for the public and private sectors to work together to deliver innovation.

Building your consortium

A robust European research consortium structure is the basis for the highly competitive pre-award phase, but also for the post-award phase, that lead to the expected impact.

Building your consortium is key and may involve stepping out of your comfort zone. genOway, as an experienced and qualified SME partner, can help you formulate a successful consortium.

‍

Our experience

genOway is a fully qualified SME partner validated by the European Commission.

We successfully participated in 13 EU programs, including one Horizon 2020 and six FP7 projects with an overall of 80 collaboration partners:

Access details at the European Commission database

Latest projects

TO_AITION

genOway is one of the 13 participants in the TO_AITION project, entitled:

"A high-dimensional approach for unwinding immune-metabolic causes of cardiovascular disease-depression multimorbidities."

‍

genOway will be in charge of designing and developing three genetically modified mouse models – one conditional Knockin and two conditional Knockouts, with the following objectives:

  • Determine the role of ATP citrate lyase in the development of atherosclerosis/cardiovascular disease-depression multimorbidity in animal models
  • Characterization of novel causal mechanisms of atherosclerosis/cardiovascular disease-depression comultimorbidity

For all project details please consult:

‍

ANTILAPSE

genOway is one of four participants in the European project ANTILAPSE (part of Eurostars), entitled:

"Combating cancer patient relapse and treatment resistance: Development of the first drug to prevent cancer-cell DNA mutagenesis."